Last reviewed · How we verify
Midazolam Injectable Solution
At a glance
| Generic name | Midazolam Injectable Solution |
|---|---|
| Also known as | Dormicum |
| Sponsor | University of Washington |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparison of Prolotherapy and Rehabilitation Treatments in Low Back Pain (CPRTLBP) (NA)
- An Open-label, DDI Study to Investigate the Effects of Amlitelimab on the PK of Selected Cytochrome P450 Substrates (PHASE1)
- Effect of Estrogen Treatment on Drug Metabolism and Transport (PHASE4)
- Intranasal Dexmedetomidine Versus Oral Midazolam Premedication for Postoperative Negative Behavior Changes in Children (PHASE4)
- Remimazolam vs. Midazolam for Sedation and Cognitive Outcomes in Orthopedic Surgery (PHASE3)
- Ketamine in OCD: Efficacy and Effects on Stress and Cognition (NA)
- Effect & Safety of Inhaled Isoflurane vs IV Midazolam for Sedation in Mechanically Ventilated Children 3-17 Years Old (PHASE3)
- This Study in Healthy Men Tests How Different Doses of BI 1358894 Are Taken up in the Body and How Well They Are Tolerated. The Study Also Tests How BI 1358894 Affects the Way the Body Breaks Down Midazolam (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |